Isomazole

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525384

CAS#: 86315-52-8 (free base)

Description: Isomazole is a potent inotropic agent, inhibiting both PDE3 and PDE4.

Chemical Structure

img
Isomazole
CAS# 86315-52-8 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 525384
Name: Isomazole
CAS#: 86315-52-8 (free base)
Chemical Formula: C14H13N3O2S
Exact Mass: 287.07
Molecular Weight: 287.337
Elemental Analysis: C, 58.52; H, 4.56; N, 14.62; O, 11.14; S, 11.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 87359-33-9 (HCl)   86315-52-8 (free base)    

Synonym: Isomazole

IUPAC/Chemical Name: 2-(2-Methoxy-4-methylsulfinylphenyl)-3H-imidazo[4,5-c]pyridine

InChi Key: JQUKCPUPFALELS-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H13N3O2S/c1-19-13-7-9(20(2)18)3-4-10(13)14-16-11-5-6-15-8-12(11)17-14/h3-8H,1-2H3,(H,16,17)

SMILES Code: O=S(C1=CC=C(C(N2)=NC3=C2C=NC=C3)C(OC)=C1)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 287.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Borasio PG, Cervellati F, Pavan B, Pareschi MC. "Low" concentrations of sodium fluoride inhibit neurotransmitter release from the guinea-pig superior cervical ganglion. Neurosci Lett. 2004 Jul 1;364(2):86-9. PubMed PMID: 15196683.

2: Utkan T, Yildirim MK, Yildirim S, Sarioglu Y. Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro. Int J Impot Res. 2001 Feb;13(1):24-30. PubMed PMID: 11313837.

3: Dorigo P, Floreani M, Santostasi G, Maragno I, Danieli-Betto D, Germinario E, Magno SM, Primofiore G, Marini AM, Da Settimo F. Pharmacological characterization of a new Ca(2+) sensitizer. J Pharmacol Exp Ther. 2000 Dec;295(3):994-1004. PubMed PMID: 11082434.

4: Andreani A, Leoni A, Morigi R, Bossa R, Chiericozzi M, Galatulas I. In vivo cardiotonic activity of aryl- and pyridyl-substituted fused imidazoles. Arzneimittelforschung. 1998 Mar;48(3):232-5. PubMed PMID: 9553678.

5: Van der Ent M, Remme WJ, Bartels GL, De Leeuw PW, Van Hoogenhuyze DC, Kruijssen DA. Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizer. J Card Fail. 1997 Dec;3(4):277-86. PubMed PMID: 9547442.

6: De Mey C, Erb K, Schroeter V, Belz GG. Differentiation of inodilatory responses by non-invasive measures of cardiovascular performance in healthy man. Int J Clin Pharmacol Ther. 1996 Dec;34(12):525-32. PubMed PMID: 8996846.

7: Hata K, Goto Y, Futaki S, Takasago T, Saeki A, Nishioka T, Suga H. Effects of milrinone and sulmazole on left ventricular mechanoenergetics in canine hearts. J Card Fail. 1996 Sep;2(3):203-13. PubMed PMID: 8891859.

8: Bossa R, Bissoli M, Chiericozzi M, Cozzi R, Galatulas I, Salvatore G. Reduction of adriamycin cardiotoxicity by enoximone. Anticancer Res. 1996 Jan-Feb;16(1):141-3. PubMed PMID: 8615599.

9: De Mey C. Method specificity of the auscultatory estimates of the inodilatory reduction of diastolic blood pressure based on Korotkoff IV and V criteria. Br J Clin Pharmacol. 1995 May;39(5):485-90. PubMed PMID: 7669483; PubMed Central PMCID: PMC1365054.

10: Kelso EJ, McDermott BJ, Silke B. Actions of the novel vasodilator, flosequinan, in isolated ventricular cardiomyocytes. J Cardiovasc Pharmacol. 1995 Mar;25(3):376-86. PubMed PMID: 7769801.

11: Kelso EJ, McDermott BJ, Silke B. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes. Biochem Pharmacol. 1995 Feb 14;49(4):441-52. PubMed PMID: 7872950.

12: Borasio PG, Pavan B, Fabbri E, Ginanni-Corradini F, Arcelli D, Poli A. Adenosine analogs inhibit acetylcholine release and cyclic AMP synthesis in the guinea-pig superior cervical ganglion. Neurosci Lett. 1995 Jan 23;184(2):97-100. PubMed PMID: 7724055.

13: Tuininga YS, van Veldhuisen DJ, Crijns HJ, van den Broek SA, Brouwer J, Haaksma J, Man in 't Veld AJ, Lie KI. Exploratory study of the effects of single doses of isomazole on hemodynamics and heart rate variability parameters in chronic heart failure. J Cardiovasc Pharmacol. 1995 Jan;25(1):81-6. PubMed PMID: 7723357.

14: McGarry SJ, Williams AJ. Activation of the sheep cardiac sarcoplasmic reticulum Ca(2+)-release channel by analogues of sulmazole. Br J Pharmacol. 1994 Apr;111(4):1212-20. PubMed PMID: 8032608; PubMed Central PMCID: PMC1910124.

15: Sitsapesan R, Williams AJ. Regulation of the gating of the sheep cardiac sarcoplasmic reticulum Ca(2+)-release channel by luminal Ca2+. J Membr Biol. 1994 Feb;137(3):215-26. PubMed PMID: 8182731.

16: Kelso EJ, McDermott BJ, Silke B. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes. Br J Pharmacol. 1993 Dec;110(4):1387-94. PubMed PMID: 8306078; PubMed Central PMCID: PMC2175870.

17: Hirasawa A, Awaji T, Hosono M, Haruno A, Hashimoto K. Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models. J Cardiovasc Pharmacol. 1993 Dec;22(6):847-51. PubMed PMID: 7509903.

18: Wu Z, Awaji T, Abe H, Motomura S, Hashimoto K. Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias. Jpn J Pharmacol. 1993 Nov;63(3):399-404. PubMed PMID: 8107332.

19: Coates WJ, Connolly B, Dhanak D, Flynn ST, Worby A. Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase. J Med Chem. 1993 May 14;36(10):1387-92. PubMed PMID: 8388468.

20: Borasio PG, Cervellati F, Fabbri E. Sulmazole effects on PGE2 and D-Ala2-Met-enkephalinamide modulation of cyclic AMP synthesis and neurotransmitter release in a sympathetic ganglion. Neurosci Lett. 1992 Sep 28;145(1):105-8. PubMed PMID: 1361043.